FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3179662608> ?p ?o ?g. }

• W3179662608 abstract "Interleukin-12 (IL12) is a proinflammatory cytokine produced by activated antigen-presenting cells that induces differentiation of Th1 cells and increased proliferation and cytotoxicity of T and NK cells. Stimulation of these cells by IL12 leads to production of high levels of IFNγ. These immune-stimulating aspects of IL12 may help to establish an inflammatory tumor microenvironment critical for anti-tumor responses. Preclinical studies in mice revealed that native IL12 can dramatically shrink syngeneic tumors, however clinical studies in humans resulted in severe toxicity and a small therapeutic window, limiting response rates. Prior work at Xencor demonstrated that reduced-potency IL15/IL15Rα-Fc fusion proteins exhibited superior pharmacokinetics, pharmacodynamics, and safety in non-human primates through reduction of receptor-mediated clearance. Applying similar principles to IL12, we created IL12 heterodimeric Fc-fusions (IL12-Fc) with reduced potency to improve tolerability, slow receptor-mediated clearance, and extend half-life.IL12 is a heterodimeric protein consisting of two subunits, so we engineered IL12-Fc fusions by fusing the IL12p35 subunit to one side of a heterodimeric (and inactive) Fc domain, and the IL12p40 subunit to the other side. These Fc-fusions were tuned for optimal activity by introducing amino acid substitutions at putative receptor-interface positions and screening for reductions of in vitro potency. In vitro activity was assessed on human PBMCs by measuring signaling in a STAT4 phosphorylation assay and IFNγ production in a mixed-lymphocyte reaction (MLR). In vivo anti-tumor activity of human IL12-Fc were assessed in a human PBMC engrafted mouse MCF7 tumor model. Surrogate mouse IL12-Fc were evaluated in additional murine tumor models. Tolerability and pharmacodynamic activity were assessed in non-human primates.IL12-Fc were produced with good yield and purity. An IL12-Fc potency series was created, and variants had up to a 10,000-fold reduction in STAT4 signaling potency and IFNγ production in an MLR assay compared to native IL12-Fc. Anti-tumor activity was achieved with potency-reduced IL12-Fc as a single-agent and in combination with anti-PD1, with weaker variants maintaining anti-tumor activity at higher dose levels. Analysis of peripheral lymphocytes indicated increased numbers of T and NK cells as well as activation of CD8+ T cells. Increased expression of immune checkpoints including PD1 was also observed. Analysis of serum indicated up to 200-fold increases in IFNγ levels. Combined, these data indicate that potency-reduced IL12-Fc retain strong anti-tumor activity, while potentially overcoming safety and tolerability issues related to narrow therapeutic index associated with recombinant native IL12 or IL12-Fc agents.Citation Format: Matthew J. Bernett, Ke Liu, Christine Bonzon, Rumana Rashid, Nicole Rodriguez, Nargess Hassanzadeh-Kiabi, Connie Ardila, Katrina Bykova, Michael Hackett, Norm Barlow, Irene Leung, Duc-Hanh Nguyen, Araz Eivazi, Seung Y. Chu, Rajat Varma, Umesh S. Muchhal, John R. Desjarlais. IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compared to native IL12 agents [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1743." @default.
• W3179662608 created "2021-07-19" @default.
• W3179662608 creator A5003990311 @default.
• W3179662608 creator A5024855811 @default.
• W3179662608 creator A5053102971 @default.
• W3179662608 creator A5055529107 @default.
• W3179662608 creator A5056285194 @default.
• W3179662608 creator A5057110529 @default.
• W3179662608 creator A5057688250 @default.
• W3179662608 creator A5059606700 @default.
• W3179662608 creator A5060094291 @default.
• W3179662608 creator A5060614785 @default.
• W3179662608 creator A5071386810 @default.
• W3179662608 creator A5081606592 @default.
• W3179662608 creator A5081789226 @default.
• W3179662608 creator A5082539304 @default.
• W3179662608 creator A5083819170 @default.
• W3179662608 creator A5084510695 @default.
• W3179662608 creator A5087205608 @default.
• W3179662608 date "2021-07-01" @default.
• W3179662608 modified "2023-10-17" @default.
• W3179662608 title "Abstract 1743: IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compared to native IL12 agents" @default.
• W3179662608 doi "https://doi.org/10.1158/1538-7445.am2021-1743" @default.
• W3179662608 hasPublicationYear "2021" @default.
• W3179662608 type Work @default.
• W3179662608 sameAs 3179662608 @default.
• W3179662608 citedByCount "0" @default.
• W3179662608 crossrefType "proceedings-article" @default.
• W3179662608 hasAuthorship W3179662608A5003990311 @default.
• W3179662608 hasAuthorship W3179662608A5024855811 @default.
• W3179662608 hasAuthorship W3179662608A5053102971 @default.
• W3179662608 hasAuthorship W3179662608A5055529107 @default.
• W3179662608 hasAuthorship W3179662608A5056285194 @default.
• W3179662608 hasAuthorship W3179662608A5057110529 @default.
• W3179662608 hasAuthorship W3179662608A5057688250 @default.
• W3179662608 hasAuthorship W3179662608A5059606700 @default.
• W3179662608 hasAuthorship W3179662608A5060094291 @default.
• W3179662608 hasAuthorship W3179662608A5060614785 @default.
• W3179662608 hasAuthorship W3179662608A5071386810 @default.
• W3179662608 hasAuthorship W3179662608A5081606592 @default.
• W3179662608 hasAuthorship W3179662608A5081789226 @default.
• W3179662608 hasAuthorship W3179662608A5082539304 @default.
• W3179662608 hasAuthorship W3179662608A5083819170 @default.
• W3179662608 hasAuthorship W3179662608A5084510695 @default.
• W3179662608 hasAuthorship W3179662608A5087205608 @default.
• W3179662608 hasConcept C137061746 @default.
• W3179662608 hasConcept C149532602 @default.
• W3179662608 hasConcept C150903083 @default.
• W3179662608 hasConcept C154317977 @default.
• W3179662608 hasConcept C192562407 @default.
• W3179662608 hasConcept C202751555 @default.
• W3179662608 hasConcept C203014093 @default.
• W3179662608 hasConcept C207001950 @default.
• W3179662608 hasConcept C502942594 @default.
• W3179662608 hasConcept C55493867 @default.
• W3179662608 hasConcept C57992300 @default.
• W3179662608 hasConcept C86803240 @default.
• W3179662608 hasConcept C95444343 @default.
• W3179662608 hasConceptScore W3179662608C137061746 @default.
• W3179662608 hasConceptScore W3179662608C149532602 @default.
• W3179662608 hasConceptScore W3179662608C150903083 @default.
• W3179662608 hasConceptScore W3179662608C154317977 @default.
• W3179662608 hasConceptScore W3179662608C192562407 @default.
• W3179662608 hasConceptScore W3179662608C202751555 @default.
• W3179662608 hasConceptScore W3179662608C203014093 @default.
• W3179662608 hasConceptScore W3179662608C207001950 @default.
• W3179662608 hasConceptScore W3179662608C502942594 @default.
• W3179662608 hasConceptScore W3179662608C55493867 @default.
• W3179662608 hasConceptScore W3179662608C57992300 @default.
• W3179662608 hasConceptScore W3179662608C86803240 @default.
• W3179662608 hasConceptScore W3179662608C95444343 @default.
• W3179662608 hasLocation W31796626081 @default.
• W3179662608 hasOpenAccess W3179662608 @default.
• W3179662608 hasPrimaryLocation W31796626081 @default.
• W3179662608 hasRelatedWork W2023541280 @default.
• W3179662608 hasRelatedWork W2067960249 @default.
• W3179662608 hasRelatedWork W2119697230 @default.
• W3179662608 hasRelatedWork W2134417758 @default.
• W3179662608 hasRelatedWork W2145306431 @default.
• W3179662608 hasRelatedWork W2297634741 @default.
• W3179662608 hasRelatedWork W2396932951 @default.
• W3179662608 hasRelatedWork W2499862928 @default.
• W3179662608 hasRelatedWork W2800648910 @default.
• W3179662608 hasRelatedWork W2953758866 @default.
• W3179662608 isParatext "false" @default.
• W3179662608 isRetracted "false" @default.
• W3179662608 magId "3179662608" @default.
• W3179662608 workType "article" @default.